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nonreceptor 22Abstract Background: The protein tyrosine phosphatase non receptor 22 gene (PTPN22) is an
important negative regulator of signal transduction through the T-cell receptors. Recently a
single-nucleotide polymorphism (SNP) 1858 C/T within this gene was shown to be a risk factor
for several autoimmune diseases.
Aim: To analyze a possible association between 1858 C/T SNP and T1DM in Egyptian cohort.
Patients and methods: Patients with T1DM and healthy controls were genotyped for the 1858 C/T
SNP in PTPN22 gene.
Results: A non-significant association between PTPN22 1858 C/T SNP and T1DM was found.
1858T/T genotype was not observed more frequently in T1DM patients compared to control
subjects.
Conclusion: In concordance with previous data establishing PTPN22 1858 C/T SNP association
with several autoimmune diseases, our findings deny further evidence that the PTPN22 gene may
play an important role in the susceptibility to T1DM.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Pediatric
Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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Type 1 diabetes mellitus (T1DM) is an autoimmune disease
characterized by autoimmune destruction of the insulin-
producing pancreatic b-cells, resulting in a lack or absence of
insulin production and disturbed glucose homeostasis.1
T1DM is precipitated by interplay between inherited traits as
well as poorly understood environmental factors.2 Genetic pre-
disposition plays amajor role as well as a number of co-inherited
susceptibility alleles interspersed throughout the genome have
been identified. HLA class II locus and the genes for insulin
(INS), cytotoxic T lymphocyte antigen-4 (CTLA4), and lym-
phoid tyrosine phosphatase (PTPN22) are the major predispos-
ing genes.3 PTPN22 and CTLA-4 are responsible for
intracellular signaling pathways that affect T-cells activity level
and their effector functions and prevent spontaneous activation
of auto-reactive cells and development of autoimmunity.4
PTPN22 gene is located on chromosome 1p13.3-13.1 that
encodes the lymphoid tyrosine phosphatase (LYP), which is
expressed exclusively in hemopoietic cells.5 In T cells, LYP is
an important negative regulator of signal transduction through
the T-cell receptor (TCR) and forms a complexwith the negative
regulatory kinase C-SRC kinase (Csk).6 A commonmutation in
PTPN22 gene is a C to T substitution at position 1858 (C1858T)
that results in substitution of amino acid arginin with trypto-
phan at codon 620 (R620W), which is located in the LYP–Csk
interactionmotif. Thismutation leads to partial or complete dis-
ruption of the binding of PTPN22 Csk.7 Carriers of C1858T
show reduced signal transduction through the TCR receptor.8
The aim of our work is to study the association between
1858C/T polymorphism and T1DM in Egyptian children.
Patients and methods
Patients
This case-control study was carried out in the period from
2011 to January 2012, it was conducted on 80 subjects that
were divided into 2 groups; group 1: included 50 previously
diagnosed T1DM patients (28 male and 22 female), with age
2–12 years from those attending the Diabetic Endocrine and
Metabolic Pediatric Unit (DEMPU) clinic of the new chil-
dren’s hospital, Cairo University, group 2: included 30 healthy
age and sex matched controls (17 male and 13 female), with
age range 2–12 years with no family history of T1DM or any
other autoimmune disease as a control group. The study
protocol was approved by the University’s Research Ethics
Committee and was conducted in accordance with the
University’s bylaws for human research, and informed
consents were obtained from one of the parents.
All subjects were subjected to full history taking, full clini-
cal examination, and anthropometric data collection including;
height, and weight, Body Mass Index (BMI) (kg/m2) was cal-
culated for the patients. The BMI from 18.50 to 24.99 kg/m2
is considered normal, <18.5 kg/m2 is considered underweight
and P25 kg/m2 is considered overweight.
Investigations
Six milliliters venous blood was withdrawn from all partici-
pants and divided into three tubes: 2 ml blood was collectedin plain tubes, serum was separated for routine laboratory
investigations, 2 ml blood was collected in sterile EDTA vacu-
tainers for HbA1c assay, and 2 ml blood was collected into
another sterile EDTA vacutainers and stored at 20 C for
the assay of PTPN22 C1858T genotypes.
Routine laboratory investigations included: AST, ALT,
Urea, creatinine, total cholesterol, triglycerides, and urinary
albumin/creatinine ratio using Beckman Coulter CX9 PRO
autoanalyzer. HbA1c assay was done using Dimension RxL
MaX autoanalyzer.
For genomic DNA analysis: it was performed in the Molec-
ular Unit of the Chemical Pathology department. DNA was
extracted from peripheral blood leukocytes using Genomic
DNA Qiagen Purification Kit (Qiagen GmbH, Qiagen
Strasse1, 40724 Hilden Germany).
Determination of PTPN22 1858 C/T gene polymorphism
was done using polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP) method, using Hybaid
thermal cycler Promega Corporation, USA, for the PCR.
The amplification mixture contained 12.5 ll of PCR master
mix supplied by BioFlux (Catalog number BSA09M2-Japan)
(containing Taq DNA polymerase in 2X buffer, MgCl2 and
dNTPs), 1 ll of each primer, 5 ll of template DNA and
5.5 ll sterile DW to a final volume of 25 ll. Each PCR run
had a blank without genomic DNA as a negative control.
The primer sequences were as follows: forward 50-ACTGA
TAATGTTGCTTCAACGG-30 and reverse 50-TCAC
CAGCTTCCTCAACCAC-3050.9 The PCR protocol was:
initial denaturation at 94 C for 5 min, 35 cycles consisting
of 60 s at 94 C, 60 s at 62 C, and 60 s at 72 C, and final
elongation step at 72 C for 10 min. Amplified products were
digested using RsaI (SibEnzyme) overnight at 37 C and
electrophoresed on a 2% agarose gel and detection of the
polymorphism was done using gel electrophoresis and ultra-
violet light transillumination. RsaI recognizes its target
sequence only when the PTPN22 1858C allele is present. The
1858T polymorphic allele is not digested and yields one
fragment of 218 bp, while the 1858C wild allele is digested
and yields two fragments of 176 bp and 46 bp. The 46 bp,
172 bp, and 218 bp bands indicate the CT heterozygote
genotype (Fig. 1).
Statistical analysis
Allele frequency was calculated using gene counting method
(each individual is represented by 2 alleles and allele fre-
quency = number of mutated alleles/total number of alleles).
The Chi-square test was used to compare allele and genotype
frequency among different studied groups. Quantitative data
were expressed as mean ± SD and compared using t-test when
normally distributed, and as median and range using Mann
Whitney U test when not normally distributed. P value
<0.05 is considered significant. Statistics were done using
SPSS V.15 software.Results
HbA1c, triglycerides and albumin/creatinine ratio were signif-
icantly higher in the patients group compared to the control
group. Other parameters showed no significant statistical
difference between the two groups (Table 1).
Figure 1 The genotype frequency among the studied groups. P
value <0.05 is significant. Patients: type 1 diabetes mellitus
patients. Each individual is represented by 2 alleles; C Alleles, and
T Alleles. CC genotype: wild type (CC). CT genotype: heterozy-
gous for polymorphism (CT).
Figure 2 The allele frequency among the studied groups. P value
<0.05 is significant. Patients: type 1 diabetes mellitus patients.
Each individual is represented by 2 alleles; C Alleles, and T Alleles.
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patients and control groups (47/50 representing 94% of
T1DM patients and 30/30 representing 100% of the control
group) respectively, with no significant statistical difference
between both groups (P value= 0.171) (Fig. 1). The CT geno-
type is present in 3 T1DM patients (3%) only and none of the
control while the TT genotype is absent in both groups. Each
individual is represented by 2 alleles. There is no significant dif-
ference among both groups as regards allele frequency with P
value= 0.176 (Fig. 2).
There was no statistically significant difference between the
age of onset of diabetes, gender, diabetic control using HbA1C
level, BMI and the different PTPNN22 genotypes. However,
the 3 heterozygote cases (CT) were younger at the onset of
T1DM diagnosis and underweight.
Detection of PTPN22 1858 C/T polymorphism by PCR-
RFLP, digested with RsaI shown on agarose gel electrophore-
sis was shown in Fig. 3.Table 1 Demographic and laboratory data of the studied groups.
T1DM group
Age (years) 9.1 ± 2.6
Sex (M/F) % 28/22 (56/44%
HbA1c (%) 7.8 ± 1.6
ALT (U/L) 16 ± 7
AST (U/L) 19 ± 7
Urea (mg/dl) 13.4 ± 6.7
Creatinine (mg/dl) 0.56 ± 0.14
Albumin/creatinine ratio1 (lg/mg creatinine) 13.4 (11.15–6
Total cholesterol (mg/dl) 144 ± 43
Triglycerides (mg/dl) 68 ± 30
All data are presented as mean ± standard deviation except gender whic
median and average. P-value<0.05 is significant.
T1DM: type 1 diabetes mellitus; M: male; F: female; HbA1c: glycated heDiscussion
Type I diabetes mellitus is associated with both genetic and
environmental factors.10 The genetic predisposition to T1DM
is strongly linked to MHC region, however non-HLA loci
associated genes are also considered to predispose to the risk
of T1DM. The most relevant non-HLA genes recognized to
be susceptible for T1DM are those connected with the T-cell
mediated immune response11 like PTPN22 which is the third
major locus recognized to affect T1DM risk after, HLA-DR/
DQ and the insulin gene.4
In this study PTPN22 shows no significant difference
between T1DM group and the healthy control group
(P= 0.171). Hence, we could not find an association between
PTPN22 1858 C/T polymorphism and T1DM susceptibility.
The frequency of T allele was 3% in T1DM patients, while
T allele was absent in controls. In harmony with this study,
several reports failed to find significant association between
PTPN22 1858 C/T polymorphism and T1DM susceptibil-
ity.12,9 Also in a study done on Egypt, no association between
PTPN22 C1858T polymorphism and susceptibility to systemicn= 50 Control group n= 30 P value
5.7 ± 3.2 0.000
) 17/13 (56.7/43.3) 0.701
5.05 ± 0.56 0.000
16 ± 5 0.710
17 ± 5 0.255
14.1 ± 2.3 0.568
0.51 ± 0.11 0.116
.5) 12.15 (8.2–4.5) 0.08
139 ± 19 0.586
55 ± 17 0.025
h is represented as % and albumin/creatinine ratio (1) represented as
moglobin; ALT: alanine transaminase; AST: aspartate transaminase.
50 bp ladder 
Lane 5 Lane 4 Lane 3 Lane 2 Lane 1
Figure 3 Detection of PTPN22 1858 C/T polymorphism by PCR-RFLP, digested with RsaI shown on agarose gel electrophoresis. Lane
1 = 50 bp ladder. Lanes 2 and 3 = heterozygous for polymorphism (CT) (218,172 and 46 bp). Lane 4 and 5 =Wild type (CC) (172 and
46 bp).
78 O. Elsisi et al.lupus erythromatosis was found.13 On the contrary, other
studies found significant association between 1858C/T
polymorphism and susceptibility to T1DM.14–17
The geographic and ethnic variations in T1DM may
reflect the prevalence of susceptibility genes or causal envi-
ronmental factors, or both.18 On the basis of genetics studies
in different populations, the C1858T polymorphism shows
variable frequency among populations and there is a geo-
graphic gradient with regard to the frequency of the disease
associated with T1858 allele in Europe. The highest frequency
was found in the United Kingdom (8%), Sweden (12%), and
Finland (15.5%). Even though this allele is relatively rare in
Southern European populations suggesting a Northern Euro-
pean origin and/or selective advantage for the T1858 allele in
this region (2% in Italy, 6% in Spain), the frequency
increases northward through Europe.2 While 1858 C/T poly-
morphism in PTPN22 is not relevant in susceptibility to
T1DM in Africa, Asia populations,19,20 and in the Azeri pop-
ulation of Northwest Iran,21 this strongly supports our
findings.
Our study suggests that PTPN22 1858/T gene polymor-
phism does not confer susceptibility to T1DM. Since it is
unlikely that a single defect in the PTPN22 gene is solely
responsible for the diverse T cell dysfunction observed in
T1DM, several other genes may influence the susceptibility
and clinical course through linkage disequilibrium.22 Alter-
natively, the PTPN22 gene might not harbor a risk allele
shared by all autoimmune diseases, as the PTPN22 gene
clearly contributed to the development of several other
autoimmune diseases.23 Thus, the negative results in this
study may be attributed to the ethnic variation or insuffi-
cient sample size. Furthermore, other genetic and/or envi-
ronmental factors seem to be responsible for the
susceptibility to T1DM in Egyptian children. The limited
number of patients with CT genotype of PTPN22 1858 C/T
polymorphism in the current study made the detection of
genotype association with different clinical and laboratory
parameters difficult.Conclusion
This study suggests that PTPN22 1858 C/T polymorphism
does not exhibit a significant influence on the susceptibility
or laboratory characteristics in T1DM children. However, a
larger sample size is recommended before making any definite
conclusion.Conflict of interest
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